PRESS RELEASE

Kainova Therapeutics to Present Clinical and Preclinical Updates on its GPCR Programs at AACR Annual Meeting 2026

- *Phase I/II DOMISOL study design for DT-7012, a Treg-depleting anti-CCR8 antibody*
- *Comprehensive preclinical characterization of DT-7012, highlighting its differentiated binding and effector-function properties*
- *Biomarker analyses from the completed Phase I EPRAD study of DT-9081, an EP4 receptor antagonist*

Montreal, Canada – Strasbourg, France – Boston, United States, March 26, 2026: Kainova Therapeutics ("the Company"), a key player for breakthrough treatments in immuno-oncology and inflammation, today announced that it will present clinical and preclinical updates from its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, California.

The presentations reflect the breadth of the Company's GPCR-modulating programs, from preclinical mechanism of action studies to clinical trial design and translational biomarker evaluation.

Poster Presentation Details:

Poster Title: Comprehensive characterization of DT-7012, a highly differentiated anti-CCR8 depleting antibody
Session: Monoclonal Antibodies and Antibody-Cytokine Platforms
Date & Time: April 21, 2026, 9:00 AM -12:00 PM PST
Location: Poster Section 9
Poster Board Number: 27
Abstract Presentation Number: 4356

DT-7012 is a Phase I/II differentiated anti-CCR8 monoclonal antibody candidate designed to selectively deplete highly immunosuppressive regulatory T cells (Tregs). This poster will describe the preclinical characterization of DT-7012, including its unique CCR8 binding profile, effector-function potency, and selectivity compared with other clinical-stage CCR8-targeting antibodies.

Poster Title: Design and rationale of DOMISOL, a first-in-human Phase I/II study of DT-7012 (NCT06819735) in advanced solid tumors
Session: Phase I and Phase II Clinical Trials in Progress
Date & Time: April 21, 2026, 2:00-5:00 PM PST
Location: Poster Section 51
Poster Board Number: 19
Abstract Presentation Number: CT285

This poster will outline the design and scientific rationale of DOMISOL, the ongoing first-in-human, multicenter, open-label Phase I/II trial evaluating safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of DT-7012 in patients with advanced solid tumors.

Poster Title: Biomarker dynamics in the completed Phase I study of DT-9081: An analysis of ex vivo cytokine stimulation, urinary PGEM, and tumoral biomarkers in advanced solid tumors
Session: Biomarkers Predictive of Therapeutics Benefit 5
Date & Time: April 21, 2026, 9:00 AM -12:00 PM PST
Location: Poster Section 42
Poster Board Number: 5
Abstract Presentation Number: 5239

This poster will present integrated biomarker analyses from the completed Phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, including ex vivo cytokine stimulation, urinary PGEM, tumor-based biomarkers, and plasma cytokine dynamics.

Stephan Schann, Chief Scientific Officer of Kainova Therapeutics said: *"We look forward to sharing these insights with the scientific community at AACR, as they reflect the scientific foundation of our GPCR-modulating programs and the thoughtful approach guiding their advancement. These learnings across preclinical, translational, and clinical contexts are essential to understanding where GPCR modulation may meaningfully shape therapeutic development."*

ENDS

For more information, please contact:
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens
+44 (0) 203 882 9621
kainova@optimumcomms.com

For French media:
communication@kainovatx.com

About Kainova Therapeutics

Kainova Therapeutics is a clinical-stage biopharmaceutical company, headquartered in Montreal, Canada, driving a robust pipeline of breakthrough therapies that precisely modulate G protein-coupled receptors (GPCRs) with a focus on immuno-oncology and inflammation. Kainova Therapeutics' key programs include a unique clinical-stage Treg-depleting anti-CCR8 antibody with differentiated competitive features and a first-in-modality pre-IND stage biased antagonist of PAR2.

By unlocking challenging and unexploited GPCR targets through its integrated discovery-to-clinic approach that integrates deep biological knowledge, Kainova Therapeutics delivers highly differentiated therapies grounded in rigorous science and designed to improve therapeutic efficacy. Recognized for a solid track record of collaborations with major pharma, physicians and KOLs worldwide, Kainova Therapeutics brings scientific excellence to the development of GPCR-modulating therapies.

Operating in North America, France, and Australia, Kainova Therapeutics applies smart trial designs, capital efficiency, and operational rigor across its programs. As GPCRs gain renewed attention as next-generation drug targets, Kainova Therapeutics is uniquely positioned to lead this evolving field. For more information, please visit www.kainovatx.com

About DT-7012

DT-7012 is a differentiated immunotherapy candidate designed to selectively deplete highly immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment (TME) by targeting CCR8 through potent ADCC and ADCP mechanisms. CCR8 has emerged as a highly compelling target in immuno-oncology due to its predominant expression on intratumoral Tregs, and DT-7012 is designed to exploit its biology with best-in-class properties. Distinct from other CCR8-targeting therapies in development, DT-7012 binds a broader range of CCR8 receptor variants and maintains depletion efficiency even in CCL1-rich environments by preventing ligand-induced receptor internalization. This enables sustained Treg depletion in challenging TMEs and supports restoration of immune competence, offering a potential new treatment option for patients unresponsive to existing immunotherapies.

About DT-9081

DT-9081 is an oral EP4 receptor antagonist designed to reverse Prostaglandin E2 (PGE2)-mediated immunosuppression within the tumor microenvironment. PGE2, produced by COX-2 positive tumors, promotes tumor progression and dampens antitumor immunity. By selectively inhibiting EP4 receptor, DT-9081 aims to restore immune competence and improving responsiveness to anticancer therapies, including

chemotherapy and certain ICIs. Preclinical studies have shown robust antitumor activity in triple-negative breast cancer, sarcoma, and colorectal cancer models, both as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors. DT-9081 is supported by a comprehensive biomarker strategy enabling precise monitoring of EP4 receptor engagement during treatment and helping inform clinical positioning, de-risk development, and guide an efficient, informative clinical trial strategy.